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Metabolic Activation and Lung Toxicity: A
Basis for Cell-Selective Pulmonary Damage
by Foreign Chemicals
by Michael R. Boyd*
The lungs may be exposed to potentially toxic metabolites that are either formed in situ or which are
present in the circulation. Therefore, pulmonary injury may be a prominent effect of certain classes of
chemicals thatundergo bioactivation in the body. The specific types oflungcellsdamaged maydependupon
factors such as preferential exposure or accumulation ofparent compounds and/or metabolites, differences
in cellular defense mechanisms, or the specific mechanism of activation of the toxicant. Prior knowledge
about the metabolism, disposition and mechanism of bioactivation of a particular compound may allow
prediction ofthe type oflung cell damage it is likely to produce. Conversely, morphological observations of
characteristic types of cell-specific injury in the lung may suggest a likely biochemical mechanism of
toxicity for the particular chemical involved.
MetabolicActivationandPulmonary
Toxicity
The lung canmetabolize certain chemicals via enzyme
systems very similar to those in the liver. The lung may
be a site of many different kinds ofbiotransformations,
including oxidations, reductions and conjugations. As in
the liver, metabolism not only may result in the
detoxification or removal of a chemical from the body,
but also can lead to products that are more toxic than
theparentchemical. Drugdetoxificationreactions occur-
ringinthe lung maybe very important in protectingthe
lung locally against toxic materials produced in situ or
reaching the lung in the bloodstream, but negligible
when considered in terms ofthe overall in vivo disposi-
tion ofthe agents. On the other hand, metabolites that
cause irreversible or cumulative changes in the lung
may be of major consequence.
The general area of metabolic activation and pulmo-
nary injury already has been reviewed in detail else-
where (1). Therefore, in the present. review some
conceptual models are presented briefly, and the major
emphasis is aimed at the implications these models may
have for chemical-induced damage to specific types of
cells in the lungs.
Based on available experimental data from a number
of laboratories, three different mechanistic models of
lung injury involving metabolic activation may be
described (1). In one instance the protoxin may be
activated primarily in the liver, and the ultimate toxic
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product is carried to the lungs viathe bloodstream (Fig.
1). A likely example of a toxicity occurring in this
fashion is the severe pulmonary damage caused by
certain pyrrolizidine alkaloids, such as monocrotaline
(1,2). This substance apparently is metabolized exclu-
sivelyin the liverto ahighly reactive pyrrolic derivative
that can irreversibly bind to the liver and the lung,
leading to damage of both of these tissues. The toxic
pyrrolic metabolite, although very reactive, does have
sufficient stability that a portion ofthe amount formed
can escape from the liver into the circulation.
Inanothertoxicitymodel, thecyclicreduction/oxidation
ofthe parent compound leads to high rates ofconsump-
tion of cellular cofactors such as NADPH and the
production oflarge amounts ofsuperoxide (Fig. 2) (1,3).
Conceivably, either the intense depletion of essential
cellular reducing equivalents and/or the generation of
highly reactive oxygen radicals could lead directly to
theexpressionofpulmonaryinjuryand/orcouldcontrib-
ute to a severe compromise of pulmonary antioxidant
defense mechanisms. Pulmonary injury in this manner
may be exemplified by the herbicide paraquat and also
possibly by nitrofurantoin. Some typical features in the
in vivo toxicity shared by these two compounds include
its enhancement by dietary deficiencies of antioxidants
(e.g., vitamin E and selenium) or by exposure to
oxygen-enriched atmospheres. These toxicological simi-
larities suggest these agents may be capable ofinjuring
the lung through common mechanisms. This hypothesis
seems further supported by in vitro observations show-
ing that pulmonary microsomes promoted high rates of
NADPH oxidation and superoxide generation by both
compounds (presumably involving a transient free-M. R. BOYD
FIGURE 1. Pulmonary toxicity model involving reactive metabolites
formed primarily in liver.
FIGURE 2. Pulmonary toxicity model involving "oxygen activation."
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FIGURE 3. Pulmonarytoxicity modelinvolving insitumetabolism to
reactive metabolite.
radical metabolite), even though the chemical struc-
tures of the two parent compounds are very different.
The superoxide produced can be shown to lead also to
other oxygen metabolites, such as singlet oxygen,
hydrogen peroxide, and hydroxyl radical. Any, or all, of
these products conceivably could contribute to lung
injury, possibly by stimulating the peroxidative decom-
position of essential cellular lipids, although the ulti-
mate mode oflung damage by such products is yet to be
fully defined. Studies concerning the mechanism oflung
injury are reviewed in detail by Bus and Gibson (3).
A third model for pulmonary injury involving meta-
bolic activation involves the generation of the ultimate
toxic metabolite(s) directly within the lung itself (Fig.
3). This mechanism may apply equally well to com-
pounds entering the lung either from the inhaled air or
from the circulation. A prototypical example of this
type oftoxicity is that caused by ingestion or injection
of 4-ipomeanol (1). This compound,
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4-Ipomeanol
a furan derivative, was originally isolated and shown to
be the major toxic substance in moldy sweet potatoes
which had been responsible for severe lung injury and
death in cattle. Indeed, itwas the unusually severe, and
remarkably selective, pulmonary injury and its associa-
tion with the ingestion ofaforeign substance that led to
the interest in the chemical and biological properties of
this agent, and its mechanism of toxicity.
4-Ipomeanol causes severe pulmonary damage not
only in cattle but also in numerous other animal species
thathavebeentested. Anextensive seriesofexperimental
studies over the past few years have shown that
pulmonary injury by 4-ipomeanol is caused not by the
parentcompound itselfbutby ahighlyreactive, alkylat-
ingmnetabolite of4-ipomeanolproducedby acytochrome
P-450-mediated oxidative activation of the parent
compound. The formation of the ultimate lung-toxic
metabolite(s) of 4-ipomeanol occurs within the lung
itself (1).
Although 4-ipomeanol is the most extensively investi-
gated compound that is activated in situ to a lung-toxic
product, this same kind of mechanism may also be
applicable to a variety of other compounds (1). For
instance, it appears that many othertoxic furan deriva-
tives in addition to 4-ipomeanol may also act similarly
(4). Examples of other lung-toxic furans include the
synthetic furan carbamate derivative CMF (5), the
atmosphericcontaminant3-methylfuran(6), andanother
natural product, perilla ketone (7,8). There is evidence
that hydrocarbons such as bromobenzene (9) and naph-
thalene (10,11) may be metabolized to toxic products in
thelungs. Haloalkanes, exemplifiedbycarbontetrachlo-
ride (12), may also damage the lungs, apparently due to
the in situ generation of toxic metabolites. There are
some data, too, that suggest thiourea (13) and deriva-
tives such as a-naphthylthiourea (14) require in situ
metabolic activation to produce their lung-damaging
effects. Other compounds for which there is some
evidence that metabolism may play a key role in the
expression of toxicity include 3-methylindole (15) and
butylated hydroxytoluene (16).
MetabolicBasisforthePulmonary
Clara Cell as a Target for
Environmental Toxicants
There has been considerable interest in the pulmo-
nary drug-metabolizing enzymes, particularly the cyto-
chrome P-450 monooxygenase system and its localiza-
tion in specific lung cell populations. The basis for this
emphasis resides inthe likelyimportance ofthis system
inmediating the fornation ofreactive toxic metabolites
fromnumerous different structuralclasses ofchemicals,
including many cytotoxic or carcinogenic agents that
affectthelungs. Suchchemicalsmaybeinhaled, ingested,
or injected, and they may come from many sources,
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including industrial products or by-products, naturally
occurring substances, and drugs. Metabolic activation
of toxins in specific lung cell- types could result in
especially high susceptibility of these cells to the
adverse effects. This might, in turn, lead to serious
perturbations both in the normal pulmonary cell-cell
relationships and in nonrespiratory metabolic and other
functions of specific lung cell families.
Cellular Location of Cytochrome P-450
Monooxygenase Activity in Lung: Studies
with 4-Ipomeanol
The pulmonary toxin 4-ipomeanol provided a useful
tool to investigate the location(s) of the cytochrome
P-450 system invivo inlungcells forseveral reasons. (1)
The compound is metabolized to a highly reactive
alkylating agent that covalently binds to macromole-
cules immediately at its site of formation. (2) Tissue
sections can be washed free ofunbound 4-ipomeanol or
metabolites, leaving behind only the covalently bound
products. (3) Autoradiography can be used to visualize
the covalently bound products in fixed lung tissue from
animals dosed with radiolabeled 4-ipomeanol.
When the lung sections of such animals were exam-
ined by light microscopic autoradiography, the localiza-
tion of silver grains showed that the covalently bound
ipomeanol metabolite was located predominantly in the
nonciliated pulmonary bronchiolar (Clara) cells of the
terminal bronchioles (17). Relatively little or no silver
grains were found in the ciliated bronchiolar cells or in
parenchymalcellssuchastheTLypes I orIIpneumocytes.
The above studies provided the basis for our conclu-
sion that Clara cells are an important cellular site of
cytochrome P-450 enzyme activity in lung (17). Further
substantiation ofthis view was provided by subsequent
investigations byDevereuxetal. (18) onmonooxygenase
activities in isolated lung cell preparations, and by
immunohistochemical studies by Serabjit-Singh et al.
(19) using antibodies against apurified lung cytochrome
P-450.
Recently the metabolic activation of4-ipomeanol was
studied in isolated rabbit lung cells (20). The highest
rates of P-450-mediated metabolism of 4-ipomeanol
were observed in isolated Clara cells. A significant
amount ofactivity, albeit much less than in Clara cells,
also was seen in isolated alveolar Type II cells.
Other recent studies compared the metabolism of
4-ipomeanol in rabbit hepatic and pulmonary micro-
somes and in reconstituted systems containing purified
cytochromes P-450 (21). These results have helped
clarify the basis for the high efficiency ofmetabolism of
4-ipomeanol by the lungs. Although it is clear that the
two major isozymes of P-450 found in rabbit lung are
also present in rabbit liver, the relative concentrations
of these isozymes (with respect to the total P-450
content) in the two tissues are vastly different. As a
consequence ofthis, the P-450 systems oflung and liver
have distinct substrate specificities. The difference in
specificity between the P-450 systems of lung and liver
and the highly localized nature ofthe pulmonary system
are important factors in the tissue and cell-specific
toxicity of4-ipomeanol. The two majorpulmonary P-450
isozymes (P-450I and P-450II) both metabolize 4-ipo-
meanol and, per nanomole P-450, the lungis much more
active than the liver for this reaction. In addition, these
isozymes appear to be highly concentrated in the cell
type that is most affected by 4-ipomeanol. The pulmo-
nary P-450 system is also present inthe alveolar Type II
cell, butimmunohistochemical, electrophoreticandmeta-
bolic evidence shows that it is not nearly as concen-
trated in these cells as it is in the Clara cell. In the liver,
P-450I and P-450II appear to be somewhat evenly
distributed throughout thetissue, therebylesseningthe
chances ofcritical concentrations oftoxic metabolites of
4-ipomeanol being produced in a given hepatocyte. On
the other hand, conditions that favor the metabolism of
4-ipomeanol appear to be maximized in the Clara cell of
the lung.
Toxicological Significance of the
Cytochrome P-450 Enzyme System in
Clara Cells
The presence of a cytochrome P-450 system in Clara
cells is of potentially broad toxicological significance.
Many cytotoxic and/or carcinogenic chemicals require
activation by this enzyme system. Thus, the Clara cells
would be likely primary targets for the adverse effects
of such chemicals and/or they may serve as major sites
forproductionofproximateorultimatetoxic/carcinogenic
metabolites that act on other cells. This is vividly
illustrated by the severe and preferential damage of
pulmonary Clara cells in vivo following injection of
4-ipomeanol (17). Other studies showing preferential
damage or destruction of Clara cells by 3-methylfuran,
carbon tetrachloride and a variety ofother agents have
furthersupportedtheimportanceofthedrug-metabolizing
capacity of Clara cells in acute chemical-induced lung
injury (1). The possible importance of Clara cells in
environment-associated chronic lung disease also is a
questionneedingfurtherattention. Thehighxenobiotic-
metabolizing capacity and the high susceptibility of
Clara cells to environmental chemicals conceivably
could be important factors in the pathogenesis of
chronic obstructive small airway disease, a problem of
major public health significance. Finally, investigations
such as those reported by Reznik-Schuller and Lijinsky
(22) and by Kauffman et al. (23) with certain nitroso
derivatives provide examples ofthe induction oftumors
of apparent Clara cell origin, which, at least in some
instances, may result from the preferential activation of
the carcinogens in the Clara cells.
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OtherLungCellsasPotentialTargets
for Toxic Chemicals Requiring
Metabolic Activation
Other Bronchiolar Cells
Autoradiographic studies with relatively high doses
of 4-ipomeanol and 3-methylfuran show some covalent
binding ofthese compounds to ciliated cells, albeit to a
much smaller extent than to nonciliated (Clara) cells (1);
further studies are needed to determine whether the
smaller, but significant, amounts of covalent binding of
these toxins to ciliated cells is mediated by enzyme
activities present in the ciliated cells or whether it is
due to metabolites formed in adjacent Clara cells.
Because the ciliated cells apparently are derived from
Clara cells (24), it would not be surprising if they
possessed at least some metabolic activity toward
xenobiotic substrates.
The xenobiotic-metabolizing potential of the APUD
(amine precursor uptake and decarboxylation) cells
present in the bronchial epithelium is not known. This
metabolic potential is of interest because the APUD
cells have been suggested as the site of origin of
small-cell tumors of lung. However, APUD cells are
relatively difficult to study in this respect because they
occur only rarely in the airway epithelium of adult
animals.
Alveolar Epithelium Cells
Histochemical studies (25) suggested the presence of
some xenobiotic-metabolizing activity in pulmonary
alveolar epithelium. Isolated pulmonary Type II cells
also have been shown to have some drug-metabolizing
capability (18). Carbon tetrachloride, which probably
requires metabolic activation to damage lung cells, is
capable ofdamaging T5ype II pneumocytes in addition to
pulmonary Clara cells (12). It is of interest that
bronchiolar cells and alveolar epithelial cells share a
common embryologic origin (26); perhaps they likewise
might share similarities in their capacity to metabolize
certain foreign compounds.
Another toxic agent of potential relevance is 3-
methylindole. In certain species (ruminants) this agent
is capable of damaging both bronchial epithelium and
Type I pneumocytes, and it has been speculated that
the compound might require metabolic activation to
exertitstoxiceffect (15). Unfortunately, 3-methylindole
does not seem to reproducibly cause lung damage in
species more convenient for laboratory studies, such as
mice and rats.
Butylated hydroxytoluene (BHT) causes damage to
Type I pneumocytes in mice but apparently not in rats.
There is evidence that BHT may undergo metabolism-
related covalent binding tolungtissue and thatthis may
be related to its pulmonary toxicity in vivo (16).
Vascular Endothelium
By virtue of its location at a site for maximum
exposure to reactive metabolites reaching the lung by
way of the bloodstream, the pulmonary vascular endo-
thelium would be expected to be aprimary site fortoxic
lung damage from preformed reactive products or
metabolites reaching the lungs from the bloodstream.
Studiesshowinglungvasculardamagebythepyrrolizidine
alkaloids and their pyrrolic metabolites are consistent
with this view. At present, however, there are no clear
examples ofpulmonary endothelial cell toxicities occur-
ring by a mechanism involving in situ activation.
However, the toxic thioureas may merit further investi-
gation in this regard, since these compounds damage
the vascular endothelium, and there is some evidence
thattheyneed tobe activated bymetabolism inthe lung
(1). Interestingly, the activation of these compounds
may occur by a cytochrome P-450-independent system
(14).
Other Pulmonary Cells
The available data are insufficient to evaluate the
possibility that other types oflung cells are targets for
primary damage by toxic metabolites. The only other
specific cell type for which relevant metabolic data
presently are available is the pulmonary alveolar
macrophage. Hooketal. (27)foundthatseveralxenobiotic-
metabolizing activities were extremely low or not
detectable in rabbit alveolarmacrophages. On the other
hand, Harris et al. (28) speculated that the alveolar
macrophages could be an important source ofdiffusible
carcinogenicmetabolites fromphagocytized foreign par-
ticulates containing adsorbed procarcinogens; the bron-
chial epithelium and the macrophages in intimate con-
tact with its surface might act in concert in metabolic
activation reactions leading to carcinogenesis.
It likewise can be speculated that, if the necessary
xenobiotic-metabolizingactivitiesweresufficientlyhigh,
the metabolic activation of certain foreign compounds
by alveolar macrophages conceivably could lead directly
to acute damage of these cells and might thereby
compromise the efficiency of an important defense
mechanism of the lung. Such a possibility may be
worthy offurtherinvestigation ifsuitable models can be
identified for study.
Use of Cell-Specific Toxins in Experimen-
tal Studies
Tbxins which cause cell-specific pulmonary damage
(e.g., by virtue of their in situ metabolic activation in
target cells) may provide useful tools to study the
physiologic functions of individual lung cell types.
Cell-specific toxins also may be useful for the study of
pulmonary defense mechanisms involving cellular re-
generation. Forexample,TypeIIpneumocytesproliferate,
repopulate the alveolar walls, and differentiate intoMETABOLIC ACTIVATION AND TOXICITY 51
lype I alveolarcells afterprimarydamage ordestruction
ofType I cells (29). In a similar way, pulmonary Clara
cells appear to be responsible for repopulation and
repair ofdamaged bronchiolarepithelium (24). Itwillbe
of interest to explore further the pathophysiologic
consequences of damage to these proliferative cell
populations. Simultaneous environmental exposures to
multiple agents conceivably could lead to damage both
to highly susceptible cell populations, such as Type I
alveolar cells or the ciliated bronchiolar cells, and to
reparative cell populations, such as the Type II
pneumocytes or the Clara cells, and might thereby
resultin especially disastrous toxicologic consequences.
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